Shaheen Alanee, MD
Urology · Lafayette, INNPI 1326231390
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,850 of the $10,767 with a category attached, or 63.6%. 9 manufacturers reported payments, led by AstraZeneca at 54.9% of the total. Reporting peaked in 2019 at $5,253 and has fallen 99.7% since, to $17 in 2025.
Across 19 payments — averaging $566.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Pfizer$2K
- Astrazeneca UK Limited$1K
- Axonics, Inc.$764
- Janssen Scientific Affairs, LLC$758
- Boston Scientific$147
- plus $261 from 3 others
Across 90 payments — averaging $576.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$50K
- Genentech, Inc.$2K
What the payments were for
- Consulting fees$1,83217%
- Speaking & faculty fees$6,85064%
- Grants$7507%
- Travel & lodging$7897%
- Food & beverage$4474%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $5,914 |
| Pfizer | 1 | $1,850 |
| Astrazeneca UK Limited | 1 | $1,074 |
| Axonics, Inc. | 5 | $764 |
| Janssen Scientific Affairs, LLC | 1 | $758 |
| Boston Scientific | 4 | $147 |
| Medtronic | 1 | $138 |
| Astellas Pharma US Inc | 1 | $100 |
| 180 Medical, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TALZENNA$1,850
- Axonics r-SNM System$625
- Bulkamid$625
How this compares
$10,767 in reported general payments places this provider in the 75th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxybutynin Chloride ErOxybutynin Chloride | 46 | $796 |
| Tamsulosin Hcl | 12 | $185 |
Paid to pharmacies, not to this prescriber.
Other urology in Lafayette
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
- Matthew MellonCarmel$159K
- James BailenJeffersonville$143K
- Greg SteinbockJeffersonville$134K
- Eugene ConeGreenwood$114K
- Jason KovacCarmel$112K
- Helen BernieIndianapolis$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.